Dr Falutz is involved in several research endeavors related to aging, metabolic complications, and body composition changes in HIV patients. He collaborates with American, Canadian and European investigators on studies of the role of both loss of muscle mass and obesity on clinical and functional outcomes in HIV patients. He was the international co-primary investigator for several multi-national studies of a novel growth-hormone releasing factor, tesamorelin, developed locally in Montreal, which was shown to be effective in reducing visceral adiposity in treated HIV patients with lipodystrophy. This drug is now approved in both Canada and the US. He is currently the lead Canadian investigator for a multi-national NIH sponsored study (REPRIEVE Study- Randomized Study to Prevent Vascular Events in HIV) to investigate whether the non-lipid-lowering effects of a statin drug, pitavastatin, can prevent cardiovascular disease in treated HIV patients at low cardiac risk as determined using traditional risk assessment tools. He is actively studying the development of premature frailty in aging HIV patients and is involved in several multi-national collaborative studies using a validated frailty metric, the Frailty Index (FI), to identify HIV patients who are frail and may benefit from targeted interventions to improve functional status. He has begun the Comprehensive HIV and Aging Initiative (CHAI) at the Chronic Viral Illness Service, The goal of this program is to identify aging HIV patients whose evolving medical, clinical, and psychosocial needs can be better served via an interdisciplinary approach.